Perceptive Advisors LLC Coherus Bio Sciences, Inc. Transaction History

Perceptive Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.17 - $13.87 $14.2 Million - $27.4 Million	-1,978,348 Reduced 54.27%	1,667,123 $16 Million
Q2 2022 Aug 15, 2022	SELL	$5.86 - $13.23 $6.16 Million - $13.9 Million	-1,050,377 Reduced 22.37%	3,645,471 $26.4 Million
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $7.77 Million - $11.7 Million	-711,950 Reduced 13.17%	4,695,848 $60.6 Million
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $9.94 Million - $11.9 Million	628,411 Added 13.15%	5,407,798 $86.3 Million
Q3 2021 Nov 15, 2021	BUY	$12.68 - $17.79 $1.04 Million - $1.45 Million	81,775 Added 1.74%	4,779,387 $76.8 Million
Q1 2021 May 17, 2021	BUY	$14.42 - $21.39 $371,689 - $551,348	25,776 Added 0.55%	4,697,612 $68.6 Million
Q4 2020 Feb 16, 2021	BUY	$16.56 - $18.94 $17.1 Million - $19.6 Million	1,035,351 Added 28.47%	4,671,836 $81.2 Million
Q3 2020 Nov 16, 2020	BUY	$17.41 - $19.89 $53.8 Million - $61.5 Million	3,091,200 Added 566.9%	3,636,485 $66.7 Million
Q2 2020 Aug 14, 2020	BUY	$14.43 - $19.16 $7.87 Million - $10.4 Million	545,285 New	545,285 $9.74 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.